No Data
This Is What Whales Are Betting On Gilead Sciences
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
Viiv's Dovato as Effective as Gilead' Biktarvy for HIV but With Less Weight Gain
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients